Juno Diagnostics, a San Diego, CA-based company focused on improving access to vital genetic health information and led by industry experts, closed an expanded Series A financing round of $25m.
The round was led by the Perceptive Xontogeny Venture (PXV) Fund.
The company intends to use the funds to support clinical validation studies, product development, and commercial launch of its product offerings for noninvasive prenatal testing (NIPT).
Led by Dirk van den Boom, Founder and Chief Executive Officer, Mathias Ehrich M.D., Chief Scientific Officer, and Jim Chauvapun, Chief Operations Officer, Juno Diagnostics is developing genetic testing solutions to improve access to vital health information. The company’s lead product is an NIPT solution that simplifies sample collection and improves access to high quality genetic testing results.
FinSMEs
12/05/2021